Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. (Q54940383)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5957395

7 references

19 March 2019

24 March 2019

1 August 2019

20 November 2019

27 November 2019

1 February 2021

28 October 2022

0 references

Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. (English)

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5957395

5 references

19 March 2019

24 March 2019

1 August 2019

20 November 2019

27 November 2019

Tumor necrosis factor

2 references

1 August 2019

1 February 2021

1 reference

20 November 2019

1 reference

27 November 2019

Eduardo L Grunvald

object named as

Eduardo L Grunvald

7

0 references

Niels Vande Casteele

object named as

Niels Vande Casteele

4

0 references

William Jeffery Sandborn

9

object named as

William J Sandborn

1 reference

Europe PubMed Central

13 June 2018

Jeffrey R Curtis

8

object named as

Jeffrey R Curtis

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5957395

author name string

Siddharth Singh

1

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5957395

Antonio Facciorusso

2

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5957395

Abha G Singh

3

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5957395

Amir Zarrinpar

5

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5957395

Larry J Prokop

6

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5957395

language of work or name

0 references

publication date

17 May 2018

8 references

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5957395

19 March 2019

24 March 2019

1 August 2019

20 November 2019

27 November 2019

1 February 2021

28 October 2022

8 references

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5957395

19 March 2019

24 March 2019

1 August 2019

20 November 2019

27 November 2019

1 February 2021

28 October 2022

13

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5957395

e0195123

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5957395

5

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5957395

copyright license

Creative Commons Attribution 4.0 International

7 references

Europe PubMed Central

19 March 2019

Europe PubMed Central

24 March 2019

Europe PubMed Central

1 August 2019

Europe PubMed Central

20 November 2019

Europe PubMed Central

27 November 2019

Europe PubMed Central

1 February 2021

Europe PubMed Central

28 October 2022

copyright status

0 references

on focus list of Wikimedia project

0 references

Health Effects of Overweight and Obesity in 195 Countries over 25 Years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Axial spondyloarthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

The underlying inflammatory chronic disease influences infliximab pharmacokinetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Relationship of Body Mass Index to Clinical Outcomes after Infliximab Therapy in Patients with Crohn's Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Impact of Bariatric Surgery on Patients With Rheumatoid Arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Body mass index and response to infliximab in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Update on anti-tumor necrosis factor agents in Crohn disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Tumor necrosis factor inhibitors for inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Assessing bias in studies of prognostic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Body mass index influences the response to infliximab in ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Inflammatory links between obesity and metabolic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Clinical pharmacokinetics of therapeutic monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

The economic burden of obesity worldwide: a systematic review of the direct costs of obesity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Meta-analysis in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

14 June 2018

Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

16 June 2018

Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

16 June 2018

Impact of Obesity on Remission and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

16 June 2018

Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

16 June 2018

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

16 June 2018

Measures of obesity and risk of Crohn's disease and ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

16 June 2018

Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

16 June 2018

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

16 June 2018

Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Body weight, gender and response to TNF-α blockers in axial spondyloarthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

13 August 2018

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

2 November 2018

Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

30 November 2018

Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

30 November 2018

Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

30 November 2018

Adipose tissue as an endocrine organ

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5957395

30 November 2018

Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/29771924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/29771924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/29771924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Body mass index and clinical response to infliximab in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/29771924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

-174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers

1 reference

https://pubmed.ncbi.nlm.nih.gov/29771924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/29771924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/29771924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/29771924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative,

1 reference

https://pubmed.ncbi.nlm.nih.gov/29771924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0195123

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5957395

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5957395

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5957395

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54940383&oldid=1760045020"